Emergency War Surgery NATO Handbook: Part II: Response of the Body to Wounding: Chapter XI: Infection
United States Department of Defense
Peer Review Status: Internally Peer
Reviewed
|
Agent |
Mode of Action |
Antibacterial Spectrum of Clinical Importance |
Dosage |
|
Penicillin G |
Bactericidal; interferes with bacterial cell wall synthesis |
Streptococci, Pneumococci Clostridia, Neisseriae, Corynebacteria, Pasteurella multocida, Actinomyces, Treponema, Listeria |
30 mil units IV/day every 2-4 hours |
|
Ampicillin |
Bactericidal; same as above |
Hemophilus influenzae, Proteus mirabilis, Salmonallae, Shigellae and some E. coli. Gram-positive organisms as with Penicillin G |
8 gm IV/day every 6 hours |
|
Gentamicin |
Bacteriostatic; inhibition of bacterial protein synthesis |
Klebsiella sp., Aerobacter sp., Pseudomonas aeruginosa, Serratia, indole positive Proteus sp., some Methicillin-resistant Staphylococci |
5 mg/kg/day every 8-12 hours |
|
Metronidazole |
Bacteriocidal |
Gram-negative anaerobes especially Bacteriodes fragilis. Also effective against several protozoa. |
2 gm IV/day every 4 hours |
|
Cefoxitin (2nd generation cephalosporin) |
Cell wall synthesis inhibitors; stable to staphylococcal beta lactamases |
Same as above plus Bacteroides fragilis; not active against Enterobacter spp. |
12 gm IV/day every 6 hours |
|
Clindamycin |
Bacteriostatic; inhibits protein synthesis |
Gram-positive and Gram-negative anaerobes, Gram-positive aerobic cocci, Streptococcus faecalis, Clostridia |
1200-2700 mg IV/day every 6-8 hours |
All contents copyright © 1997-2000 The University of Iowa. All rights reserved.
URL: http://www.vnh.org/